Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation

Transplantation

Volumn 97, Issue 6, 2014, Pages 642-647

  Tsapepas, Demetra S ^a   Vasilescu, Rodica ^a   Tanriover, Bekir ^b   Coppleson, Yael ^a   Rekhtman, Yelena ^b   Hardy, Mark A ^b   Dube, Geoffrey ^b   Crew, R John ^b   Ratner, Lloyd E ^b   Cohen, David J ^b   Mohan, Sumit ^b  

^a NewYork Presbyterian Hospital   (United States)

^b Department of Pathology and Cell Biology Columbia University Medical Center ^*  (United States)

Author keywords

Donor specific antibodies; Graft survival; Kidney transplantation; Outcomes; Rejection rates; Repeat transplantation

Indexed keywords

ANTIBODY; BASILIXIMAB; CORTICOSTEROID; DONOR SPECIFIC ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT SATISFACTION; PRIORITY JOURNAL; RISK ASSESSMENT; SOLID PHASE ASSAY;

ACUTE DISEASE; ADULT; BIOPSY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; ISOANTIBODIES; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEW YORK CITY; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; REOPERATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896603837     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000440954.14510.6a     Document Type: Article

References (22)

1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl JMed 1999; 341: 1725.
2. SRTR O. OPTN & SRTR Annual Data Report 2010. Am J Transplant 2012; 12(suppl 1): 9.
3. Magee JC, Barr ML, Basadonna GP, et al. Repeat organ transplantation in the United States, 1996Y2005. Am J Transplant 2007; 7(5 Pt 2): 1424.
4. Coupel S, Giral-Classe M, Karam G, et al. Ten-year survival of second kidney transplants: Impact of immunologic factors and renal function at 12 months. Kidney Int 2003; 64: 674.
5. Ojo A, Wolfe RA, Agodoa LY, et al. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: Multivariate analyses fromtheUnited States RenalData System. Transplantation 1998; 66: 1651.
6. Rao PS, Schaubel DE, Wei G, et al. Evaluating the survival benefit of kidney retransplantation. Transplantation 2006; 82: 669.
7. Marcen R, Teruel JL. Patient outcomes after kidney allograft loss. Transplant Rev (Orlando) 2008; 22: 62.
8. Almond PS, Matas AJ, Gillingham K, et al. Risk factors for second renal allografts immunosuppressed with cyclosporine. Transplantation 1991; 52: 253.
9. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665.
10. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582.
11. Colombo MB, Haworth SE, Poli F, et al. Luminex technology for anti-HLA antibody screening: Evaluation of performance and of impact on laboratory routine. Cytometry B Clin Cytom 2007; 72: 465.
12. Minucci PB, Grimaldi V, Casamassimi A, et al.Methodologies for anti-HLA antibody screening in patients awaiting kidney transplant: A comparative study. Exp Clin Transplant 2011; 9: 381.
13. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19.
14. Reed EF, Rao P, Zhang Z, et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant 2013; 13: 1859.
15. Halloran PF. The clinical importance of alloantibody-mediated rejection. Am J Transplant 2003; 3: 639.
16. Terasaki PI, Cai J. Humoral theory of transplantation: Further evidence. Curr Opin Immunol 2005; 17: 541.
17. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013; 95: 410.
18. Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J AmSocNephrol 2012; 23: 2061.
19. Ojo AO,Wolfe RA,Held PJ, et al. Delayed graft function: Risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968.
20. Giral-Classe M, Hourmant M, Cantarovich D, et al. Delayed graft function of more than six days strongly decreases long-Term survival of transplanted kidneys. Kidney Int 1998; 54: 972.
21. Karpinski M, Rush D, Jeffery J, et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001; 12: 2807.
22. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.